AstraZeneca: Q3 FY 2016 Results (AstraZeneca) - Nov 12, 2016 - Anticipated top-line data from P1 trial (NCT02118337) of durvalumab + MEDI0680 in RCC in 2019; Anticipated enrollment completion (expansion) in P1 trial (NCT02013804) in advanced malignancies in Q2 2017; Anticipated top-line data from P1 trial in advanced malignancies in Q4 2016
Anticipated enrollment status • Anticipated P1 data • Oncology
|